n-3 Fatty Acids in Enteral Formula on NK Cell Activity

Effect of Immune-enhancing Enteral Nutrition Formula Enriched With Vegetable Derived n-3 Fatty Acids on NK Cell Activity in Hospitalized Patients for Rehabilitation

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03638661

Acronym

Enrollment

Registered

2018-08-20

Start date

2015-08-11

Completion date

2018-07-30

Last updated

2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Enteral Nutrition

Brief summary

The aim of our study was to investigate the NK cell activity alternations and related cytokine changes in comparison with soybean oil used formula (control) and the canola and flaxseed oil used n-3 fatty acid enriched formula (n3EN, test) with non-surgical hospitalized patients for rehabilitation.

Detailed description

Patients were randomized to receive one of two types of enteral nutrition formula: soybean oil used enteral nutrition (control), vegetable (canola, flaxseed) derived n-3 fatty acid enriched enteral nutrition (n3EN). Blood samples were collected on the first day and 14 days after consumption of each formula and anthropometric parameters were collected. Hematology and biochemical values were analyzed and NK cell activities and serum cytokine productions were measured.

Interventions

DIETARY_SUPPLEMENTvegetable (canola, flaxseed) derived n-3 fatty acid

vegetable (canola, flaxseed) derived n-3 fatty acid was used for fat source.

DIETARY_SUPPLEMENTsoybean oil

soybean oil used formula

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Masking description

The ready-to-use soybean used formula and n3EN formula had identical packaging with no differences in appearance, texture, or smell.

Eligibility

Sex/Gender

ALL

Age

19 Years to 100 Years

Healthy volunteers

Inclusion criteria

* Patients who were admitted to the Severance Hospital Rehabilitation Department , enteral tube feeding patient, Adult male and female patients aged 19 years and over, Patients who signed the consent form

Exclusion criteria

* Patient with nausea * Patients with hepatic impairment (total bilirubin concentration\> 3.5 mg / dl) * Patients with renal impairment (serum creatinine concentration\> 3 mg / dl or requiring peritoneal or hemodialysis) diabetic patients * Patients who are undergoing chemotherapy or who are within 1 month of the end of chemotherapy * Patients whose life expectancy is less than 1 month * Pregnant women and women who are pregnant

Design outcomes

Primary

Measure	Time frame	Description
NK cell activity	Baseline	NK cell activity (%)

Secondary

Measure	Time frame	Description
cytokine values	Baseline	(IL-12, IFN-γ, IL-1β , IL-6 and TNF-α)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026